Samsung Bioepis announced on the 13th that it has unveiled the results of phase 3 clinical trials of Soliris (Eculizumab) biosimilar SB12 through the EHA annual academic conference held in Austria from the 9th to the 12th.

SB12 is the seventh biosimilar developed by Samsung Bioepis. It is the first blood disease treatment. The original Soliris is a treatment for incurable rare diseases such as PNH and aHUS developed by Alexion in the U.S. Last year, global sales amounted to $1.874 billion (approximately 2.3 trillion won).

Samsung Bioepis conducted a comparative study between SB12 and the original (ECU) in PNH patients from July 2019 to October 2021. At this conference, the results were an